AKT1 and posterior cortical atrophy: The resistance to BRD4 inhibition in SPOP-mutant PCa can be overcome by combining with AKT inhibitors, and SPOP mutations may be used as biomarkers to guide the choice of treatment options for PCa patients, including those with urgent needs seeking precision medicine, and to determine whether the treatment is valid or not114,115.